In a significant move aimed at making medication more affordable for Americans, President Trump has signed an executive order that mandates drugmakers to slash prices, potentially by up to 80%. The order includes a 30-day deadline for pharmaceutical companies to comply with these price reductions. This initiative, which includes measures to challenge drug pricing in other countries, has faced backlash from the pharmaceutical industry, which criticizes the plan as an attempt to impose excessive control on pricing. Despite the pushback, Trump remains committed to reducing costs for prescriptions and boosting domestic drug manufacturing amidst ongoing discussions about tariffs. Supporters, including the FDA commissioner, claim that this reform will lower costs across the board, while critics express skepticism about the practicality and impact of the measures. The broader aim is to align U.S. drug prices with those charged in other countries, promoting a more affordable healthcare system.